A Phase 2A Multicenter, Open Label Study of Promitil for the Treatment of Patients With Solid Tumors Associated With Deleterious Mutations Who Have Progressed After First Line Therapy
Latest Information Update: 13 May 2025
At a glance
- Drugs PL MLP (Primary)
- Indications Adenocarcinoma; Ovarian cancer; Pancreatic cancer; Pancreatic ductal carcinoma; Solid tumours
- Focus Therapeutic Use
- Sponsors Lipomedix Pharmaceuticals
Most Recent Events
- 07 May 2025 Status changed from recruiting to active, no longer recruiting.
- 03 Jul 2024 New source identified and integrated ClinicalTrials.gov: (US National Institutes of Health:NCT06478862).
- 24 Jun 2024 Status changed from planning to recruiting.